1. Cytokine pattern in patients with ST-elevation myocardial infarction treated with the interleukin-6 receptor antagonist tocilizumab
- Author
-
Ola Kleveland, Rune Wiseth, Jan Kristian Damås, Pål Aukrust, Lars Gullestad, Bente Halvorsen, Einar Hopp, Kaspar Broch, T Ueland, Anne Kristine Anstensrud, Sindre Woxholt, Bjørn Bendz, Brage H Amundsen, Nils-Einar Kløw, Ingebjørg Seljeflot, Geir Øystein Andersen, Ingvild Maria Tøllefsen, Liv Ryan, Tuva B Dahl, and Camilla Huse
- Subjects
Diseases of the circulatory (Cardiovascular) system ,RC666-701 - Abstract
Background Tocilizumab improves myocardial salvage index (MSI) in patients with ST-elevation myocardial infarction (STEMI), but its mechanisms of action are unclear. Here, we explored how cytokines were affected by tocilizumab and their correlations with neutrophils, C-reactive protein (CRP), troponin T, MSI and infarct size.Methods STEMI patients were randomised to receive a single dose of 280 mg tocilizumab (n=101) or placebo (n=98) before percutaneous coronary intervention. Blood samples were collected before infusion of tocilizumab or placebo at baseline, during follow-up at 24–36, 72–168 hours, 3 and 6 months. 27 cytokines were analysed using a multiplex cytokine assay. Cardiac MRI was performed during hospitalisation and 6 months.Results Repeated measures analysis of variance showed significant (p
- Published
- 2023
- Full Text
- View/download PDF